Survodutide is an innovative dual agonist targeting GLP-1 and glucagon receptors. In research settings, it shows strong effects on appetite regulation, fat oxidation, and energy expenditure, making it a promising candidate for studies on obesity and metabolic disorders. Preclinical data indicate significant weight reduction and improved glucose control. This material is intended strictly for laboratory and educational purposes and is not approved for human or veterinary use.
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
Formula: C192H289N47O61
CAS No.: 2805997-46-8
